Company intelligence / Profile preview
Tactogen
Palo Alto, California, United Statestactogen.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Tactogen has developed several promising candidate compounds that are well tolerated in preclinical animal studies. These retain the key therapeutic effects of MDMA—such as increased self-compassion and reduced reactivity—without depleting serotonin or causing significant adverse events like blood pressure changes. The company aims to begin clinical trials soon, focusing first on safety and then efficacy for mental health indications such as PTSD. No human clinical results have been published yet.
- Therapeutic areas
- Psychiatry
- Modalities
- Small molecules (novel entactogens/empathogens; MDMA-like compounds)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Tactogen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tactogen.